论文部分内容阅读
骨肉瘤是一种相对耐药的肿瘤,单药化疗的效果不甚理想,而且某些药物单用时所产生的严重不良反应,成为临床中行骨肉瘤化疗的障碍和难题。紫杉醇由于其独特的抗癌机制和广谱、高活性的抗癌效果,已成为世界各国近年来抗癌药研究的热点;而咖啡因作为一种生物调节剂,在多种药物的化疗中具有增效作用。以上两种药物,由于其不同的作用机制,以及在克服骨肉瘤化疗耐药方面的优势,使学者对这两种药物的联合应用有所期待。
Osteosarcoma is a relatively drug-resistant tumor, the effect of single-agent chemotherapy is not ideal, and serious adverse reactions caused by certain drugs when used alone become the obstacles and problems of clinical osteosarcoma chemotherapy. Because of its unique anti-cancer mechanism and broad-spectrum, high-activity anti-cancer effect, paclitaxel has become a hot spot in anticancer drugs in recent years in various countries in the world. As a biological modulator, paclitaxel has been widely used in the chemotherapy of various drugs Synergy. These two drugs, due to their different mechanisms of action, as well as in overcoming the advantages of chemotherapy resistance in osteosarcoma, so that scholars of these two drugs are expected to be combined.